2021
Lysosomal Storage Disorders in Children
Mistry P, Thurberg B, Grabowski G. Lysosomal Storage Disorders in Children. 2021, 570-592. DOI: 10.1017/9781108918978.032.Peer-Reviewed Original ResearchLiver diseasePost-transplant careFatty liver diseaseLong-term managementCare of childrenLiver transplantLysosomal storage disorderPediatric hepatologySurgical aspectsTreatment strategiesVariety of diseasesEarly diagnosisMetabolic disordersClinical practiceGenetic testingDiseaseStorage disorderImproved diagnosisHuge burdenHealthcare systemDisordersChildrenDiagnosisCareMajor advances
2019
Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report
Vujosevic S, Medenica S, Vujicic V, Dapcevic M, Bakic N, Yang R, Liu J, Mistry PK. Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report. World Journal Of Clinical Cases 2019, 7: 1475-1482. PMID: 31363476, PMCID: PMC6656677, DOI: 10.12998/wjcc.v7.i12.1475.Peer-Reviewed Original ResearchEnzyme replacement therapyGaucher diseaseType 1 Gaucher diseaseDeposition of glucocerebrosideGene mutationsCommon lysosomal storage disorderBone mineral densityErlenmeyer flask deformityBone painAbdominal painLysosomal storage disorderReplacement therapyMineral densityVisceral parametersDistal femurPatientsSignificant progressionClinical phenotypeSystem cellsBiallelic mutationsStorage disorderLysosomal glucocerebrosidasePainPhenotype correlationSymptoms
2016
Inherited Metabolic Disorders: Efficacy of Enzyme Assays on Dried Blood Spots for the Diagnosis of Lysosomal Storage Disorders
Verma J, Thomas DC, Kasper DC, Sharma S, Puri RD, Bijarnia-Mahay S, Mistry PK, Verma IC. Inherited Metabolic Disorders: Efficacy of Enzyme Assays on Dried Blood Spots for the Diagnosis of Lysosomal Storage Disorders. JIMD Reports 2016, 31: 15-27. PMID: 27008195, PMCID: PMC5388645, DOI: 10.1007/8904_2016_548.Peer-Reviewed Original ResearchLysosomal storage disorderNeuronal ceroid lipofuscinosisBlood spotsDiagnostic testsConsideration of therapyStorage disorderStandard of careCommon lysosomal storage disorderMajor unmet needAccurate diagnostic testHigh consanguinity rateBlood sample transportationDried Blood SpotsIrreversible complicationsI-cell diseaseAffected patientsCostly therapiesTimely diagnosisMetabolic disordersMucopolysaccharidosis IIEconomical diagnostic testsUnmet needUtility of DBSDBS resultsSpecific biomarkers
2010
Long-Term Outcomes of Liver Transplantation in Type 1 Gaucher Disease
Ayto RM, Hughes DA, Jeevaratnam P, Rolles K, Burroughs AK, Mistry PK, Mehta AB, Pastores GM. Long-Term Outcomes of Liver Transplantation in Type 1 Gaucher Disease. American Journal Of Transplantation 2010, 10: 1934-1939. PMID: 20659098, DOI: 10.1111/j.1600-6143.2010.03168.x.Peer-Reviewed Original ResearchConceptsEnzyme replacement therapyLiver transplantationGaucher diseaseLong-term enzyme replacement therapyEnd-stage liver diseaseType 1 Gaucher's diseaseSevere hepatic impairmentOrthotopic liver transplantationSuccessful liver transplantationLife-saving treatmentPrevalent lysosomal storage disorderHepatic impairmentLysosomal storage disorderYears postprocedureLiver failureLiver diseaseTerm outcomesReplacement therapyExcellent outcomesDemonstrable efficacyPatientsTransplantationPathological manifestationsDiseaseStorage disorder
2005
Guidance on the use of miglustat for treating patients with type 1 Gaucher disease
Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. American Journal Of Hematology 2005, 80: 223-229. PMID: 16247743, DOI: 10.1002/ajh.20504.Peer-Reviewed Original ResearchConceptsType 1 Gaucher diseaseEnzyme replacementGaucher diseaseSymptomatic patientsClinical manifestationsUse of miglustatProgressive lysosomal storage disorderHealth-related qualitySignificant side effectsIntravenous enzyme replacementAutosomal recessive deficiencyImiglucerase treatmentPulmonary manifestationsLysosomal storage disorderOral treatmentPulmonary diseasePatient managementSide effectsPatientsMiglustatLimited indicationsBeneficial effectsRecessive deficiencyPosition statementStorage disorder
2004
Therapeutic goals in the treatment of Gaucher disease
Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymańska A. Therapeutic goals in the treatment of Gaucher disease. Seminars In Hematology 2004, 41: 4-14. PMID: 15468045, DOI: 10.1053/j.seminhematol.2004.07.009.Peer-Reviewed Original ResearchConceptsEnzyme replacement therapyGaucher diseaseTherapeutic responseTherapeutic goalsNon-neuronopathic (type 1) Gaucher diseaseType 1 Gaucher diseaseVariable disease patternGoal of treatmentCommon lysosomal storage disorderEvidence-based consensusExtensive clinical experienceQuality of lifeImplementation of treatmentLysosomal storage disorderPulmonary diseaseReplacement therapyMultisystem conditionIndividualized managementIndividual patientsClinical experienceDisease patternsGrowth retardationDiseaseStorage disorderSkeletal pathology
2000
Inherited metabolic disease
Schilsky M, Mistry P. Inherited metabolic disease. Current Opinion In Gastroenterology 2000, 16: 219-230. PMID: 17023879, DOI: 10.1097/00001574-200005000-00004.Peer-Reviewed Original ResearchGene productsMetal metabolismGenetic disordersLysosomal storage disorderCommon lysosomal storage disorderMetabolismMetabolic diseasesStorage disorderDisease pathophysiologyDiscoveryGenesProteinGaucher diseaseNew informationTherapeutic approachesRecombinant enzyme replacement therapyWilson's diseaseIdentification